CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB032

Oral Cancer Screening and Testing

Defines BCBSOK reimbursement and coding stance for oral cancer screening and high-risk HPV testing in oropharyngeal squamous cell carcinoma; applies to providers submitting claims to Blue Cross Blue Shield of Oklahoma.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLAB032

Change TypeRevised (content and literature review)

Effective DateNov 1, 2023

Next Review Date

Key ActionProviders must submit accurate documentation and appropriate HIPAA-approved codes; BCBSOK may request additional documentation and apply claim review and code edit protocols.

SourceLink

POLICY UPDATE CHANGES

Reimbursement information revised for clarity and title changed from Oral Screening Lesion Identification Systems and Genetic Screening.

New policy created on 11/1/2022.

1.0policy version

2023-11-01effective date

2023-07-17approval date

CPCPLAB032identifier

Coverage Criteria

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLAB032

Change TypeRevised (content and literature review)

Effective DateNov 1, 2023

Next Review Date

Key ActionProviders must submit accurate documentation and appropriate HIPAA-approved codes; BCBSOK may request additional documentation and apply claim review and code edit protocols.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria for HPV testing in oropharyngeal cancer

Reimbursement may be available under specific clinical indications and is subject to plan documents and product applicability.

ALL of the following

ALL of the following
- The patient has a diagnosis of oropharyngeal squamous cell carcinoma.
AND ONE of the following test methods
- mRNA expression testing that detects HPV E6/E7.
- Immunohistochemistry testing for high‑risk HPV.
ALL of the following
- The specific product’s coverage rules apply; not all requirements apply to each product — providers must review Plan documents for eligibility.
ALL of the following
- Claims must use valid HIPAA‑approved code sets and are subject to claim review and code edits; BCBSOK may request additional documentation as needed.

Provider Documentation and Governance

Documentation Required

Submit accurate documentation and HIPAA-approved coding; be prepared for claim review

Providers must submit accurate documentation of services performed and submit claims using valid HIPAA‑approved code sets and industry-standard coding guidelines. Claims are subject to code edit protocols and claim review; upon request, BCBSOK may require the provider to submit additional documentation.

Use valid HIPAA-approved code sets and appropriate code combinations.
Code claims per industry coding guidelines (e.g., UB, AMA/CPT, HCPCS, ICD-10, NDC, DRG, CMS/NCCI).
Claims are subject to code edits and claim review; provide additional documentation upon BCBSOK request.

Denial Risk

Plan documents and provider contracts govern; BCBSOK retains discretionary authority

When this CPCP conflicts with a member’s plan document or a provider contract, the plan document or provider contract governs. BCBSOK retains reasonable discretion in interpreting and applying this policy and has full and final discretionary authority as allowed by applicable plan documents.

Plan documents (e.g., Certificates, benefit booklets, Summary Plan Descriptions) take precedence over this CPCP.
Provider contracts take precedence over this CPCP where applicable.
BCBSOK may interpret and apply the policy using reasonable discretion and has final discretionary authority to the extent allowed by plan documents.

Definitions and Coding Expectations

Lab management reimbursement criteria — key facts

ScopeBCBSOK has implemented lab management reimbursement criteria for oral cancer screening and testing; not all requirements apply to each product.

Provider responsibilityProviders are urged to review plan documents to determine eligible coverage for services rendered.

Product variabilityApplicability of specific lab management requirements varies by product—check memberâs plan documents.

Policy identifierPolicy Number: CPCPLAB032; Effective Date: 2023-11-01.

Coding expectations — required code sets and guidelines

Required code setsClaims must use valid HIPAA-approved code sets (eg, CPT, HCPCS, ICD-10, NDC, UB).

Industry guidelinesCoding should follow industry standard guidelines including UB Editor, AMA CPT, CPT Assistant, ICD-10 CM/PCS, DRG rules, and CMS NCCI policies/edits.

Claim review and editsClaims are subject to code edit protocols and claim review; additional documentation may be requested by BCBSOK.

Provider responsibilityProviders are responsible for submission of accurate documentation and appropriate code combinations.

OpenPayer

Oral Cancer Screening and Testing

Coverage Criteria

Procedure Codes and Coding Notice

Provider Documentation and Governance

Definitions and Coding Expectations